Impaired rib bone mass and quality in end-stage cystic fibrosis patients

Mailhot, Geneviève; Dion, Natalie; Farlay, Delphine; Rizzo, Sébastien; Bureau, Nathalie J.; Jomphe, Valérie; Sankhe, Safiétou; Boivin, Georges; Lands, Larry C.; Ferraro, Pasquale; Ste‐Marie, Louis‐Georges

doi:10.1016/j.bone.2017.02.007

Cited by 16 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Microradiography-based matrix mineralization data were previously shown to correlate with tissue-level bone strength ( 39 ). The digital microradiography method used in the current study was validated and used in previous clinical studies ( 31 , 40 , 41 ). As expected for a potent remodeling inhibitor, denosumab increased the overall degree of mineralization ( i.e., DMB), and reduced the heterogeneity of mineralization (HI), compared with placebo.…”

Section: Discussionmentioning

confidence: 99%

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

Dempster

Brown

Fahrleitner‐Pammer

et al. 2018

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

View full text Add to dashboard Cite

ContextDenosumab is a potent antiresorptive agent that reduces fractures in postmenopausal women with osteoporosis.ObjectiveDetermine effects of up to 10 years of denosumab on bone histology, remodeling, and matrix mineralization characteristics.Design and SettingInternational, multicenter, randomized, double-blind trial [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM)] with a long-term open-label extension.PatientsPostmenopausal women with osteoporosis (92 women in FREEDOM, 46 in extension) who provided iliac bone biopsies, including 11 who provided biopsies at multiple time points.InterventionsFREEDOM subjects were randomized 1:1 to subcutaneous denosumab 60 mg or placebo every 6 months for 3 years. Long-term extension subjects continued receiving denosumab, open-label, for 7 additional years.OutcomesBone histology, histomorphometry, matrix mineralization.ResultsTen-year denosumab biopsies showed normal histology. Bone histomorphometry indicated normal bone structure and reduced bone remodeling after 10 years of denosumab, similar to levels after 2 and/or 3 and 5 years of denosumab. The degree of mineralization of bone was increased and mineralization heterogeneity was reduced in the denosumab years 2/3 group vs placebo. Changes in these mineralization variables progressed from years 2/3 to year 5 of denosumab, but not thereafter.ConclusionsDenosumab for 2/3, 5, and 10 years was associated with normal histology, low bone remodeling rate, increased matrix mineralization, and lower mineralization heterogeneity compared with placebo. These variables were unchanged from year 5 to year 10. These data, in combination with the maintenance of low fracture rates for up to 10 years as previously reported with denosumab therapy, suggest that strong, prolonged remodeling inhibition does not impair bone strength.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

Dempster

Brown

Fahrleitner‐Pammer

et al. 2018

The Journal of Clinical Endocrinology &Amp; Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…The 40 abstracts selected in the review included 2438 patients with CF; 6 studies included a control group, giving a total number of 594 controls . One study compared the BC of patients with CF to existing reference values obtained from a healthy age‐matched and gender‐matched population .…”

Section: Resultsmentioning

confidence: 99%

“…The 40 abstracts selected in the review included 2438 patients with CF; 6 studies included a control group, giving a total number of 594 controls. [14][15][16][17][18][19] One study compared the BC of patients with CF to existing reference values obtained from a healthy age-matched and gender-matched population. 20 A longitudinal study had the smallest sample size (6 patients), 21 whereas a cross-sectional study included the largest number of patients with CF (138).…”

Section: Sample Size and Study Designmentioning

confidence: 99%

Tools and Methods Used for the Assessment of Body Composition in Patients With Cystic Fibrosis: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

Background Cystic fibrosis (CF) is characterized by changes in fat mass and lean body mass that may have important prognostic value. We aim to appraise the type and frequency of application of body composition (BC) methods in child and adult patients with CF. Methods We used 4 databases (Embase, PubMed, Scopus, and Web of Science) to perform the literature search. The search was conducted from January 2017 to February 2017. Two independent reviewers selected articles based on titles and abstracts to check eligibility for inclusion. All study designs or types of articles (abstract, full text) were considered. Results Eighty‐four full‐text articles and 40 studies presented only as abstracts were selected. Sixty‐four studies included children and adolescents (age range of 0.1–18 years), and 41 studies recruited adults (range of 18–57 years); 13 studies included both age groups. Dual‐energy X‐ray absorptiometry (DXA) was used in 56 studies (33.9%), and bioelectric impedance analysis (BIA) was used in 12 studies (9.7%), whereas 38 studies (30.6%) combined different methods (up to 5 different methods) to assess BC. Conclusions The results show a large variability in the application of BC methods in patients with CF that makes the comparison between studies difficult. The only methods with a sufficient body of literature are DXA and BIA.

show abstract

“…Low bone mineral density (BMD) is a common complication of CF, and microarchitecture assessment by high‐resolution peripheral scanner showed impaired volumetric density . The severity of the lung disease is the main determinant of bone loss, leading to increased fracture risk, selectively in the spine and ribs . Nevertheless, despite the improvement of care over recent years, a significant number of patients with CF had low BMD Z scores and reported fractures .…”

Section: Metabolic Bone Diseasementioning

confidence: 99%

“…40 The severity of the lung disease is the main determinant of bone loss, 41,42 leading to increased fracture risk, 43 selectively in the spine and ribs. 44,45 Nevertheless, despite the improvement of care over recent years, a significant number of patients with CF had low BMD Z scores and reported fractures. 46 The pathophysiology is thought to be multifactorial, and recent data suggest a direct role for CFTR protein dysfunction.…”

Section: Me Taboli Cboned Is E a S Ementioning

confidence: 99%

Long‐term extrapulmonary comorbidities after lung transplantation in cystic fibrosis: Update of specificities

Jardel

Reynaud

Durieu

2018

Clinical Transplantation

View full text Add to dashboard Cite

Lung transplantation (LT) is the standard therapeutic option for cystic fibrosis (CF) patients with end-stage lung disease. Both conditions lead to extrarespiratory complications, such as diabetes, renal insufficiency, bone disease, and cancer. The purpose of this study was to provide an update of the nonrespiratory comorbidities following LT in adult patients with CF and their specificities regarding their multisystemic underlying condition despite their younger age compared to other patients undergoing LT. Diabetes, renal insufficiency, metabolic bone disease, hypertension, liver disease, and cancer are the comorbidities considered in this review. The increase in CF adults living with a lung transplant justifies an update of knowledge for this specific situation (the prevalence of these complications, underlying risk factors), to provide better medical care and establish early diagnosis strategies.

show abstract

Impaired rib bone mass and quality in end-stage cystic fibrosis patients

Cited by 16 publications

References 29 publications

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

Tools and Methods Used for the Assessment of Body Composition in Patients With Cystic Fibrosis: A Systematic Review

Long‐term extrapulmonary comorbidities after lung transplantation in cystic fibrosis: Update of specificities

Contact Info

Product

Resources

About